Literature DB >> 23979746

Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.

Aylin Babalik1, Ismail Hakki Ulus, Nadi Bakirci, Tulin Kuyucu, Huseyin Arpag, Lale Dagyildizi, Esen Capaner.   

Abstract

Plasma isoniazid and rifampin concentrations, but not pyrazinamide and ethambutol concentrations, were decreased by about 50% (P < 0.05) in diabetic pulmonary tuberculosis patients. The prevalences of subnormal plasma isoniazid, rifampin, pyrazinamide, and ethambutol concentrations were 49% or 100% (P < 0.01), 66% or 100% (P < 0.05), 30% or 50% (P = 0.198), and 32% or 21% (P = 0.742) in nondiabetic or diabetic tuberculosis patients, respectively. These data show that plasma concentrations of isoniazid and rifampin were greatly reduced in diabetic tuberculosis patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979746      PMCID: PMC3811326          DOI: 10.1128/AAC.01345-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

2.  Therapeutic drug monitoring in the treatment of active tuberculosis.

Authors:  Aylin Babalik; Aylin Babalik; Sharyn Mannix; Denis Francis; Dick Menzies
Journal:  Can Respir J       Date:  2011 Jul-Aug       Impact factor: 2.409

3.  Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.

Authors:  Hanneke M J Nijland; Rovina Ruslami; Janneke E Stalenhoef; Erni J Nelwan; Bachti Alisjahbana; Ron H H Nelwan; Andre J A M van der Ven; Halim Danusantoso; Rob E Aarnoutse; Reinout van Crevel
Journal:  Clin Infect Dis       Date:  2006-08-22       Impact factor: 9.079

4.  The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics.

Authors:  A Pablos-Méndez; J Blustein; C A Knirsch
Journal:  Am J Public Health       Date:  1997-04       Impact factor: 9.308

Review 5.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Incidence of pulmonary tuberculosis among diabetics.

Authors:  S J Kim; Y P Hong; W J Lew; S C Yang; E G Lee
Journal:  Tuber Lung Dis       Date:  1995-12

7.  Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients.

Authors:  R Singla; N Khan; N Al-Sharif; M O Ai-Sayegh; M A Shaikh; M M Osman
Journal:  Int J Tuberc Lung Dis       Date:  2006-01       Impact factor: 2.373

8.  Type 2 diabetes and multidrug-resistant tuberculosis.

Authors:  Susan P Fisher-Hoch; Erin Whitney; Joseph B McCormick; Gonzalo Crespo; Brian Smith; Mohammad H Rahbar; Blanca I Restrepo
Journal:  Scand J Infect Dis       Date:  2008

9.  Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study.

Authors:  Claudia Caroline Dobler; Jeffrey Ronald Flack; Guy Barrington Marks
Journal:  BMJ Open       Date:  2012-02-13       Impact factor: 2.692

10.  Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence.

Authors:  Catherine R Stevenson; Nita G Forouhi; Gojka Roglic; Brian G Williams; Jeremy A Lauer; Chirstopher Dye; Nigel Unwin
Journal:  BMC Public Health       Date:  2007-09-06       Impact factor: 3.295

View more
  22 in total

Review 1.  Diabetes and Tuberculosis.

Authors:  Blanca I Restrepo
Journal:  Microbiol Spectr       Date:  2016-12

2.  Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity.

Authors:  B G J Dekkers; O W Akkerman; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

3.  Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.

Authors:  Maxwell T Chirehwa; Helen McIlleron; Lubbe Wiesner; Dissou Affolabi; Oumou Bah-Sow; Corinne Merle; Paolo Denti
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

4.  Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India.

Authors:  Geetha Ramachandran; Hemanth Kumar Agibothu Kupparam; Chandrasekaran Vedhachalam; Kannan Thiruvengadam; Vijayalakshmi Rajagandhi; Azger Dusthackeer; Ramesh Karunaianantham; Lavanya Jayapal; Soumya Swaminathan
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 5.  Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.

Authors:  Roger K Verbeeck; Gunar Günther; Dan Kibuule; Christian Hunter; Tim W Rennie
Journal:  Eur J Clin Pharmacol       Date:  2016-06-15       Impact factor: 2.953

6.  Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment.

Authors:  Omamah Alfarisi; Vidya Mave; Sanjay Gaikwad; Tushar Sahasrabudhe; Geetha Ramachandran; Hemanth Kumar; Nikhil Gupte; Vandana Kulkarni; Sona Deshmukh; Sachin Atre; Swapnil Raskar; Rahul Lokhande; Madhusudan Barthwal; Arjun Kakrani; Sandy Chon; Amita Gupta; Jonathan E Golub; Kelly E Dooley
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

7.  Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.

Authors:  A K Hemanth Kumar; V Chandrasekaran; T Kannan; A Lakshmi Murali; J Lavanya; V Sudha; Soumya Swaminathan; Geetha Ramachandran
Journal:  Eur J Clin Pharmacol       Date:  2016-09-20       Impact factor: 2.953

Review 8.  Impact of diabetes on the natural history of tuberculosis.

Authors:  Blanca I Restrepo; Larry S Schlesinger
Journal:  Diabetes Res Clin Pract       Date:  2014-07-14       Impact factor: 5.602

9.  Tuberculosis Relapse in the Epididymis After the Completion of Nine Months of Anti-Tuberculosis Chemotherapy in a Patient with Poorly Controlled Diabetes Mellitus.

Authors:  Chikako Ichikawa; Sho Tanaka; Masahiro Takubo; Masaru Kushimoto; Jin Ikeda; Katsuhiko Ogawa; Ichiro Tsujino; Yutaka Suzuki; Masanori Abe; Hisamitsu Ishihara; Midori Fujishiro
Journal:  Ther Clin Risk Manag       Date:  2021-05-25       Impact factor: 2.423

10.  The influence of diabetes, glycemic control, and diabetes-related comorbidities on pulmonary tuberculosis.

Authors:  Chen Yuan Chiang; Kuan Jen Bai; Hsien Ho Lin; Shun Tien Chien; Jen Jyh Lee; Donald A Enarson; Ting-I Lee; Ming-Chih Yu
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.